The 6 Wall Street analysts covering Parabilis Medicines, Inc. hold a median 12-month price target of $40 — +63.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 24 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Parabilis Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (30): Smaller than most of the companies we track.
Volatility (3): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PBLS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +63.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | HC Wainwright & Co. | Initiates | Buy | $40 |
| 6 July 2026 | B of A Securities | Initiates | Buy | — |
| 6 July 2026 | B of A Securities | Initiates | Buy | $45 |
| 6 July 2026 | Guggenheim | Initiates | Buy | — |
| 6 July 2026 | Guggenheim | Initiates | Buy | $40 |
| 6 July 2026 | Leerink Partners | Initiates | Outperform | $40 |
| 6 July 2026 | Leerink Partners | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PBLS appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 1% of US stocks
Cheaper than 32% of US stocks
Cheaper than 86% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Parabilis Medicines, Inc. has a market value of $3.0B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $148K.
Net income over the same four quarters: −$170.9M, a −115483.1% net margin.
Diluted earnings per share, trailing twelve months: $−2.26.
Free cash flow in the twelve months to 30 June 2026: −$119.1M.
Trailing P/E: −13.5×; forward P/E: −11.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Parabilis Medicines, Inc. employs 145 people — $1K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Parabilis Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Parabilis Medicines presented updated interim phase I/II data for zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid. The company also outlined an FDA-aligned plan for a registrational phase III study.
Why it matters — The update provides PBLS watchers with clinical data and the company’s stated plan for further development of zolucatetide.
Parabilis reported updated Phase 1/2 results for zolucatetide in desmoid tumors: among 18 response-evaluable patients starting at 450 mg or more, the 32-week objective response rate was 72.2%, while disease control was 100% among 46 patients in that dose group. The company said it aligned with the FDA on the dose regimen and Phase 3 design, and plans to start the PEDESTAL trial in the first half of 2027.
Why it matters — The update provides clinical-trial results and regulatory-development milestones for PBLS’s zolucatetide program.
The Seeking Alpha excerpt rates Parabilis Medicines a speculative Buy, citing its peptide platform, early efficacy and favorable safety for zolucatetide, and FDA Orphan and Fast Track designations. It also points to a $125 million upfront Regeneron partnership, $1.1 billion in cash, and a projected runway into 2030.
Why it matters — The excerpt highlights the company's clinical pipeline and cash position as key factors for PBLS watchers to assess.
Parabilis Medicines plans to present updated data from the ongoing Phase 1/2 trial of zolucatetide in patients with desmoid tumors at the ESMO Congress 2026. The presentation will include findings from a dose-optimization arm intended to inform dose and regimen selection for a Phase 3 registrational trial; the company also plans a webcast on October 24, 2026.
Why it matters — The update will provide PBLS watchers with information on the clinical program and the work intended to guide Phase 3 trial planning.
Parabilis Medicines initiated a dose-ranging clinical study of zolucatetide in familial adenomatous polyposis (FAP). The new cohort builds on early clinical evidence in patients with FAP and concomitant desmoid tumors.
Why it matters — The study expands clinical evaluation of zolucatetide in FAP, a development update relevant to PBLS watchers.
The 6 Wall Street analysts covering Parabilis Medicines, Inc. have a median 12-month price target of $40, with estimates ranging from $40 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Parabilis Medicines, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Parabilis Medicines, Inc. 0 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Parabilis Medicines, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (30 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +63.7% from the last close, and Ticker Nerd's factor model ranks Parabilis Medicines, Inc. 0 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Parabilis Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $45 over the next 12 months.
Parabilis Medicines, Inc. Common Stock is the equity of Parabilis Medicines, a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for serious diseases.
The most recent item we track (MarketBeat, 24 Oct 2026): "Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027". Parabilis Medicines presented updated interim phase I/II data for zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid. The company also outlined an FDA-aligned plan for a registrational phase III study.
Parabilis Medicines, Inc. Common Stock is the equity of Parabilis Medicines, a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for serious diseases. The company uses its Helicon discovery platform to design stabilized peptides that can interact with proteins often considered difficult to target with conventional medicines. Its current pipeline includes programs aimed at intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical candidate, zolucatetide, designed to inhibit the β-catenin and TCF interaction in the Wnt/β-catenin signaling pathway. Parabilis Medicines serves the healthcare and life sciences sectors, with a particular emphasis on oncology and other diseases driven by complex protein signaling.
CEO Dr. Mathai Mammen M.D., Ph.D. · 145 employees · United States · https://parabilismed.com
